rhNGF

Phase 2Small molecule

DDompé Farmaceutici S.p.A

rhNGF is one of 109 small molecule programs targeting Glaucoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

108

Competitors

Pipeline

Status by Indication[3][1]

Indication

GlaucomaActive, not recruiting

Eye DiseaseActive, not recruiting

KeratitisActive, not recruiting

CataractActive, not recruiting

GlaucomaPhase 1

Active, not recruiting

Eye DiseasePhase 2

Active, not recruiting

KeratitisPhase 1/Phase 2

Active, not recruiting

CataractPhase 2

Active, not recruiting

Competition

Competitive Landscape

219 competitors in Cataract

#DrugCompanyPhaseTrials

Lotemax

BBausch & Lomb Incorporated

Phase 3

7 2

Isopto Carpine

AAdvanz Pharma

Phase 3

1 3

Intranasal Dexmedetomidine

BBaudax Bio

Phase 3

1 4

Mapracorat

Bayer

Phase 3

4 5

Tetracaine Hydrochloride

BBausch Health Americas, Inc.

Phase 3

1 6

Ripasudil

KKowa Research Institute, Inc.

Phase 3

2 7

Idose TR

GGlaukos Corporation

Phase 3

1 8

rhNGF

DDompé Farmaceutici S.p.A

Phase 2

1 9

Zolymbus

AbbVie

Preclinical

—10

Neurontin

VViatris Specialty LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Glaucoma1 trial

Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma

Completed·DDompé Farmaceutici S.p.A·Phase 1·NCT02855450·60 enrolled

Keratitis1 trial

Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.

Completed·DDompé Farmaceutici S.p.A·Phase 1/2·NCT01756456·174 enrolled

Efficacy1 trial

Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK

Completed·DDompé Farmaceutici S.p.A·Phase 2·NCT02227147·48 enrolled

Moderate to Severe Dry Eye1 trial

A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye

Completed·DDompé Farmaceutici S.p.A·Phase 2·NCT03982368·261 enrolled

Tics1 trial

Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers

Completed·DDompé Farmaceutici S.p.A·Phase 1·NCT01744704·74 enrolled

4 more indications

Safety and Efficacy1 trial

Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye

Completed·DDompé Farmaceutici S.p.A·Phase 2·NCT02101281·40 enrolled

Eye Disease1 trial

A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.

Completed·DDompé Farmaceutici S.p.A·Phase 2·NCT06244316·317 enrolled

Cataract1 trial

A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive Surgery

Completed·DDompé Farmaceutici S.p.A·Phase 2·NCT03035864·180 enrolled

Unspecified1 trial

Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers

Completed·DDompé Farmaceutici S.p.A·Phase 1·NCT03836859·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for rhNGF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rhNGF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rhNGF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dompé Farmaceutici S.p.A company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDompé Farmaceutici S.p.A

rhNGF

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Glaucoma1 trial

Keratitis1 trial

Efficacy1 trial

Moderate to Severe Dry Eye1 trial

Tics1 trial

Safety and Efficacy1 trial

Eye Disease1 trial

Cataract1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News